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Abstract
Background: Awake prone positioning (awake-PP) in non-intubated coronavirus disease 2019 (COVID-19) patients
could avoid endotracheal intubation, reduce the use of critical care resources, and improve survival. We aimed to
examine whether the combination of high-flow nasal oxygen therapy (HFNO) with awake-PP prevents the need for
intubation when compared to HFNO alone.
Methods: Prospective, multicenter, adjusted observational cohort study in consecutive COVID-19 patients with
acute respiratory failure (ARF) receiving respiratory support with HFNO from 12 March to 9 June 2020. Patients were
classified as HFNO with or without awake-PP. Logistic models were fitted to predict treatment at baseline using the
following variables: age, sex, obesity, non-respiratory Sequential Organ Failure Assessment score, APACHE-II, C-reactive
protein, days from symptoms onset to HFNO initiation, respiratory rate, and peripheral oxyhemoglobin saturation. We
compared data on demographics, vital signs, laboratory markers, need for invasive mechanical ventilation, days to
intubation, ICU length of stay, and ICU mortality between HFNO patients with and without awake-PP.
Results: A total of 1076 patients with COVID-19 ARF were admitted, of which 199 patients received HFNO and were
analyzed. Fifty-five (27.6%) were pronated during HFNO; 60 (41%) and 22 (40%) patients from the HFNO and HFNO +
awake-PP groups were intubated. The use of awake-PP as an adjunctive therapy to HFNO did not reduce the risk of
intubation [RR 0.87 (95% CI 0.53–1.43), p = 0.60]. Patients treated with HFNO + awake-PP showed a trend for delay in
intubation compared to HFNO alone [median 1 (interquartile range, IQR 1.0–2.5) vs 2 IQR 1.0–3.0] days (p = 0.055), but
awake-PP did not affect 28-day mortality [RR 1.04 (95% CI 0.40–2.72), p = 0.92].
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Conclusion: In patients with COVID-19 ARF treated with HFNO, the use of awake-PP did not reduce the need for
intubation or affect mortality.
Keywords: Acute respiratory failure, COVID-19, High-flow nasal oxygen therapy, Prone positioning, Mechanical
ventilation, Critical care
Background
A high number of patients with coronavirus disease 19
(COVID-19) develop severe bilateral viral pneumonia.
Many COVID-19 patients evolve to acute respiratory
distress syndrome (ARDS), characterized by profound
hypoxemia and an associated high mortality rate [1, 2].
High-flow nasal oxygen therapy (HFNO) is effective in
decreasing the need for endotracheal intubation in pa-
tients with acute hypoxemic respiratory failure (ARF)
[3]. However, the lack of proven benefits in COVID-19
patients together with the concerns of increased risk of
aerosolization led to recommending early intubation and
invasive mechanical ventilation (MV) at the beginning of
the pandemic. Due to the high infection rate of COVID-
19, this resulted in a rapid exhaustion of ICU resources
worldwide [4].
However, MV is associated with substantial risks in-
cluding ventilator-associated pneumonia, ICU-acquired
weakness, delirium, and cognitive impairment. The rec-
ognition that the potential benefits of HFNO for pre-
venting intubation and sparing critical ICU resources
could outweigh its risks soon led to guidelines and ex-
pert recommendations advocating its use during the
pandemic [5–7]. Nevertheless, when choosing HFNO to
support COVID-19-related ARF, two considerations
should be made. First, HFNO may be insufficient to cor-
rect the hypoxemia secondary to intrapulmonary shunt
and ventilation-perfusion (V/Q) mismatch. Second, it
may delay intubation and invasive MV, which may
worsen the patients’ outcome, as suggested in ARDS pa-
tients [8]. Vigorous breathing efforts in hypoxemic ARF
patients promoting further lung injury (a process known
as patient self-inflicted lung injury, P-SILI) may worsen
the outcome [9]. In this context, the use of awake prone
positioning (awake-PP) during spontaneous breathing in
non-intubated patients could contribute to a reduction
of the risk of P-SILI by promoting a more homogeneous
distribution of ventilation while improving oxygenation
and V/Q matching [10].
Several studies have shown that the combination of
awake-PP and HFNO or non-invasive ventilation (NIV)
is feasible in patients with severe COVID-19 pneumonia,
resulting in an increase in oxygenation or a decrease in
the respiratory rate and/or dyspnea [11–16]. However,
to date, it has not been established whether the combin-
ation of HFNO plus awake-PP could prevent the need
for invasive MV and decrease the need of ICU resources
in COVID-19 patients with ARF. We performed this




This is a prospective, multicenter, adjusted cohort study
of consecutive patients with COVID-19 ARDS admitted
to 36 hospitals from Spain and Andorra. The study was
approved (additional file 2) by the referral Ethics Com-
mittee (Hospital de Cruces, Vizcaya, Spain) and by all
participating centers. Each participating center consid-
ered the need for written informed consent. This study
followed the “Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE)” guidelines for
observational cohort studies [17].
Study population and data collection
Data from patients’ electronic medical records were
reviewed and collected by physicians trained in critical
care according to a previously standardized common
protocol. Each investigator had a personal username/
password and entered data into a specifically pre-
designed online data acquisition system (CoVid19.ubi-
kare.io) endorsed and validated by the Spanish Society of
Anesthesiology and Critical Care (SEDAR) (https://www.
sedar.es/images/site/REGISTRO_CRITICOS_COVID19/
MANUAL_REGISTRO_REG-SARS-COVID19.pdf). Pa-
tient confidentiality was protected by assigning a de-
identified patient code. All consecutive COVID-19 patients
included in the dataset from March 12th to June 9th, 2020,
were enrolled if they fulfilled the following criteria: (1) age ≥
18 years, (2) confirmed SARS-CoV-2 infection from a
respiratory tract sample using PCR-based tests, (3) no pre-
vious invasive MV or NIV use before starting HFNO, and
(4) peripheral oxyhemoglobin saturation (SpO2) < 93% with
a non-rebreather face mask at 15 L/min. Patients with non-
confirmed SARS-CoV-2 infection according to WHO guid-
ance and patients with no data on ventilation strategies
were excluded.
Recorded data included demographics [age, gender,
body mass index (BMI)], comorbidities, previous pharma-
cological treatments, disease chronology [time from onset
of symptoms and from hospital admission to initiation of
respiratory support, ICU length of stay (LOS)], symptoms
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at ICU admission, vital signs [temperature, mean arterial
pressure (MAP), heart rate], laboratory parameters (blood
test, coagulation, biochemical), non-respiratory Sequential
Organ Failure Assessment (non-respiratory SOFA) and
APACHE II scores, patients requiring invasive MV, pa-
tients discharged from ICU, and patients who had died or
were still under ICU care on June 28, 2020.
We defined baseline as the first day on HFNO and col-
lected a full set of data on that day. Site investigators
collected what they considered the representative data of
each day from admission to ICU discharge. We also col-
lected the “worst” values during the study period (max-
imum or minimum, depending on the variable). In the
case report form, prone position was only considered if
the duration was > 16 h/day regardless of the number of
sessions. Before data were analyzed, two independent in-
vestigators and a statistician screened for erroneous data
against standardized ranges and contacted local investi-
gators with any queries. Only validated or corrected data
were entered into the database. For the purpose of this
analysis, patients were classified into two groups: (1) pa-
tients who received HFNO + awake-PP and (2) patients
who only received HFNO. Awake-PP was indicated by
medical criteria and was not uniformly defined and pro-
tocolized for the study.
Statistical analysis
As this is an observational study, and no harm is
inflicted and no benefit associated with being in the
study we aimed to recruit as many patients as possible,
with no pre-defined sample size. Descriptive variables
are expressed as percentage, mean and standard devi-
ation (SD), or median and interquartile range (IQR), as
appropriate for each variable. We used the Student t test
or Mann-Whitney test for numerical variables and chi-
squared test or Fisher exact test for categorical variables,
to compare variables across groups. We used inverse
probability of treatment weighting to account for base-
line differences between HFNO and HFNO + awake-PP
groups. Based on the literature, we fitted logistic models
to predict treatment at baseline using the following vari-
ables as predictors of treatment: age, sex, obesity, non-
respiratory SOFA score, APACHE II, C-reactive protein
(CRP), days from symptoms onset to HFNO initiation,
respiratory rate, SpO2, and type of hospital (4 groups de-
pending on the number of enrolled patients). Weights
were calculated following the methodology described
elsewhere and a weighted population (adjusted sample)
was built subsequently [18]. To assess the relationship
among the exposure awake-PP and the probability of be-
ing intubated and mortality at day 28, time to event
curves were plotted using the Kaplan-Meier method and
analyzed with log-rank test and multivariate Cox regres-
sion analysis. For Kaplan-Meier analyses, patients with
complementary outcome were right-censored at the lon-
gest recorded length of stay. We also stratified patients
by PaO2/FiO2 below or above 100. Missing data were
not imputed. Analyses were performed on a complete
case analysis basis. All tests were two-sided, and a P
value < 0.05 was considered statistically significant. All
analyses were performed with STATA version 16.
Results
Between March 12th and June 9th, 2020, 1076 critically
ill patients admitted in 36 ICUs in Spain and Andorra
were included in the database. HFNO was used in 400
patients during their ICU stay, but in 199 patients,
HFNO was the first therapeutic option (Fig. 1). From
those 199 patients, 55 (27.6%) were pronated during
HFNO. The median time from symptom onset to hos-
pital admission and to HFNO or HFNO + awake-PP
start were 7 vs 7 days and 10 vs 11 days, respectively
(Table 1).
Fig. 1 Patient flowchart. HFNO, high-flow nasal oxygen therapy; MV,
invasive mechanical ventilation; NIV, noninvasive ventilation
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Patients’ demographics, symptoms at ICU admission,
baseline vital signs, arterial blood gases, and laboratory
findings according to HFNO or HFNO + awake-PP are
shown in Table 1, both in the original and adjusted
samples. There were no differences in the time from
symptom onset to hospital admission or onset of HFNO
(Table 1). No substantial imbalances in patients’ demo-
graphics, vital signs, arterial blood gases, and laboratory
findings at baseline were observed (Table 1). In both
samples, PaO2/FiO2 was significantly higher in the
HFNO + awake-PP group.
Table 2 shows the worst patients’ findings during the
ICU course while under HFNO treatment in the original
and adjusted samples. There were no clinically substan-
tial differences except for IL-6 and procalcitonin levels,
both being higher in HFNO patients. Mean values of
SpO2, RR, and ROX index over time in the adjusted
sample are reported in the supplemental digital content
2 (Figures 1, 2 and 3). Differences between the intubated
and non-intubated patients in the adjusted sample at
baseline and during ICU stay while treated with HFNO
are shown in the supplemental digital content 2 (Tables
1, 2, 3 and 4 and Figures 1, 2 and 3).
From 199 patients, 82 (41%) patients required intub-
ation and invasive MV: 60 (41%) and 22 (40%) in the
HFNO and HFNO + awake-PP groups, respectively
(Table 5 in the Additional file 1). The use of awake-PP
as adjunctive therapy to HFNO did not reduce the risk
of being intubated neither in the original nor in the ad-
justed samples [hazard ratio (RR) 0.87 (95% CI 0.538–
1.435), p = 0.60] and [RR 1.002 (95% CI 0.531–1.890),
p = 0.99] (Table 4). HNFO + awake-PP did also not re-
duce the risk of being intubated in the subgroups of pa-
tients with PaO2/FiO2 greater or less than 100 (Figure 4
in the Additional file 1). Time from HFNO to intubation
was longer in the HFNO + awake-PP in the original (1.0
vs 2.0 days, p = 0.055) and adjusted (2.0 vs 4.1 days, p =
0.054) samples, although differences did not reach statis-
tical significance. As of June 27, 2020, 146 (73%) patients
were discharged from the ICU with no differences be-
tween HFNO 105 (86%) patients and HFNO + awake-PP
41 (83%) patients (Table 5 in the Additional file 1). ICU
length of stay did not vary between groups (7.5 vs 8.0,
p = 0.27) (Table in the Additional file 1).
The 28-day mortality risk was not influenced by the
use of awake-PP [RR 2.411 (95% CI 0.556–10.442), p =
0.23)] (Table 3 and Fig. 2). Neither did it influence the
subgroups of patients with PaO2/FiO2 higher or less
than 100 (Figure 5 in the Additional file 1).
Discussion
In this prospective multicenter adjusted study in 199 pa-
tients with COVID-19 ARF treated with HFNO, the syn-
ergistic use of awake-PP did not reduce the intubation
rate. Although 28-day mortality was not affected, our
findings also suggest that awake-PP could have a po-
tentially negative impact as it was associated with a
delay in intubation. Our analysis does not support
widespread use of awake-PP in COVID-19 patients
with ARF treated with HFNO. However, given the ob-
servational nature of our study, these results should
be interpreted with caution and by no means consid-
ered definitive.
Published studies on the management of ARF in
COVID-19 patients have shown that the vast majority
need invasive MV with prolonged times on the ventila-
tor [19, 20]. Alternatives to invasive respiratory support
such as HFNO, a simple technique with few side effects,
have been widely used during the pandemic. Other ad-
junctive techniques, such as awake-PP, have been widely
used to correct hypoxemia and avoid the need for inva-
sive MV [11–16]. The benefits of prone positioning in
ARDS patients have been well established. Prone posi-
tioning favors lung recruitment improving V/Q mis-
match by decreasing shunt [21, 22]. The resulting more
homogeneous distribution of ventilation could decrease
the risk of ventilator-induced lung injury, a mechanism
directly related to the mortality [23]. However, the ex-
perience with awake-PP in ARDS patients treated with
HFNO is limited. The only previously published study
included 20 patients of which 9 patients (45%) required
intubation; for the 11 non-intubated patients, 8 received
HFNO + awake PP, and six of them needed escalation to
NIV [24].
Data on the use of awake-PP in COVID-19 patients is
limited to small, single-center studies or case series with
contradictory results. Elharrar et al. [11] examined the
effects of awake-PP in 24 patients receiving oxygen ther-
apy. Oxygenation improved in about one fourth of pa-
tients and deteriorated again after turning the patient to
supine. No information regarding the need for intub-
ation was provided [11]. Thompson et al. [12] in a simi-
lar population of 25 patients managed with conventional
oxygen therapy found a heterogeneous response to
awake-PP with improvements in SpO2 ranging from 1 to
37%, but 12 patients (48%) patients required intubation.
Better results were found by Ng et al. [13] who applied
daily awake-PP sessions of 5 h in 10 non-ICU patients
with only one needing intubation. Similar results were
reported by Sartini et al. [14] in 15 non-ICU patients
supported with NIV in whom awake-PP was used as a
rescue therapy, resulting in an improvement of oxygen-
ation and respiratory rate, and only one patient required
intubation. In the study by Xu et al. [15], intubation was
needed in 5 (50%) out of 10 patients managed with
HFNO plus early awake-PP 16 h/day during three
consecutive days. Finally, Coppo et al. [16] performed a
feasibility and physiological study including 56 patients
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Table 1 Baseline characteristics of the original-eligible population and weighted population
Original sample Weighted sample







Patients demographics and comorbidities
Age 63.0 [55.0–71.0]/144 60.0 [54.0–70.0]/55 0.38 60.3 60.9 0.82
Gender, female 39/143 (27.3%) 13/54 (24.1%) 0.71 28.8% 33.9% 0.62
Body mass index, kg/m2 27.3 [25.1–29.4]/120 26.8 [24.8–31.2]/49 0.75 28.6 28.2 0.66
Arterial Hypertension 60/144 (41.7%) 20/55 (36.4%) 0.52 42.8% 34.3% 0.41
Diabetes Mellitus 23/144 (16.0%) 9/55 (16.4%) 0.99 18.1% 10.7% 0.25
Chronic heart failure 2/144 (1.4%) 2/55 (3.6%) 0.30 1.4% 5.2% 0.46
Chronic renal failure 14/144 (9.7%) 4/55 (7.3%) 0.78 6.4% 6.2% 0.98
Asthma 5/144 (3.5%) 1/55 (1.8%) 0.99 7.6% 6.3% 0.87
COPD 6/144 (4.2%) 4/55 (7.3%) 0.46 4.2% 8.2% 0.44
Obesity 25/120 (20.8%) 17/49 (34.7%) 0.07 30.2% 32.4% 0.82
Dyslipidemia 15/144 (10.4%) 4/55 (7.3%) 0.59 8.1% 4.5% 0.38
Malignancy 9/144 (6.3%) 3/55 (5.5%) 0.99 4.9% 3.2% 0.68
Medical treatment
Anti-hypertensive agents 62/144 (43.1%) 19/55 (34.6%) 0.33 43.9% 35.9% 0.45
Hypoglycemic agents 18/144 (12.5%) 7/55 (12.7%) 0.99 17.8% 17.0% 0.92
Antiplatelet agents 17/144 (11.8%) 5/55 (9.1%) 0.80 8.8% 12.8% 0.55
Anticoagulants 10/144 (6.9%) 1/55 (1.8%) 0.29 10.7% 1.2% 0.014
Bronchodilators 35/144 (24.3%) 10/55 (18.2%) 0.44 22.4% 23.3% 0.93
Lipid lowering agents 8/144 (5.6%) 3/55 (5.5%) 0.99 7.8% 3.2% 0.32
Thyroid hormone replacement 10/144 (6.9%) 9/55 (16.4%) 0.058 12.4% 25.5% 0.20
Immunossupressors 9/144 (6.3%) 1/55 (1.8%) 0.29 4.1% 0% 0.050
Corticosteroids 9/144 (6.3%) 2/55 (3.6%) 0.73 4.1% 0% 0.050
Chronology
Days from symptom onset to hospital
admission
7.0 [4.0–9.0]/141 7.0 [4.0010.0]/55 0.75 7.4 7.6 0.79
Days from symptom onset to HFNO 10.0 [8.0–13.0]/142 11.0 [8.0–13.0]/55 0.44 10.1 10.2 0.99
Symptoms at ICU admission
Fever 121/144 (84.0%) 51/55 (92.7%) 0.16 87.0% 90.0% 0.70
Cough 94/144 (65.3%) 36/55 (65.5%) 0.99 69.3% 62.2% 0.50
Dyspnea 92/144 (63.9%) 39/55 (70.9%) 0.40 62.4% 73.8% 0.23
Malaise 57/144 (39.6%) 27/55 (49.1%) 0.26 42.1% 56.3% 0.19
Myalgia 22/144 (15.3%) 10/55 (18.2%) 0.66 18.0% 18.8% 0.92
Headache 12/144 (8.3%) 6/55 (10.9%) 0.58 7.8% 5.8% 0.64
Rhinorrhea 1/144 (0.7%) 1/55 (1.8%) 0.47 1.1% 3.3% 0.52
Vomiting 10/144 (6.9%) 4/55 (7.3%) 0.99 4.6% 7.9% 0.56
Arthralgia 6/144 (4.2%) 4/55 (7.3%) 0.46 3.4% 5.5% 0.63
Chest pain 12/144 (8.3%) 1/55 (1.8%) 0.11 9.2% 0% 0.006
Increased sputum 14/144 (9.7%) 6/55 (10.9%) 0.79 7.7% 11.0% 0.57
Anosmia 6/144 (4.2%) 4/55 (7.3%) 0.46 6.5% 6.5% 0.99
Pharyngodynia 5/144 (3.5%) 1/55 (1.8%) 0.99 3.5% 1.2% 0.33
Diarrhea 20/144 (13. 9%) 9/55 (16.4%) 0.65 15.8% 15.0% 0.91
Fatigue 1/144 (0.7%) 4/55 (7.3%) 0.021 0% 6.6% 0.052
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in which awake prone lasting > 3 h improved oxygenation
but not dyspnea and respiratory rate. Similar to previous
studies, this improvement in oxygenation was maintained
only in half of their patients after returning to the supine
position. Of note, awake-PP was applied earlier (median of
1.9 days) in responders. However, no differences in the
need for intubation were found between responders and
non-responders (26% vs. 30%) [16]. Those previous re-
ports together with our current study do not support the
use of awake-PP as an effective adjunctive strategy for pre-
venting intubation.
As oxygenation is generally improved on awake-PP,
one potential risk would be an undue delay in intubation
which could potentially worsen prognosis, as demon-
strated in previous studies in non-COVID-19 patients
[8]. Coppo et al. [16] did not find any differences in time
to intubation between responders and non-responders
to awake-PP in their cohort of COVID-19 patients. Our
original and adjusted data show that patients in the
HFNO + awake-PP group had a strong trend toward a
delay in intubation of 2 days; however, 28-day mortality
was similar in both treatment groups.
Table 1 Baseline characteristics of the original-eligible population and weighted population (Continued)
Original sample Weighted sample








APACHE II 11.0 [8.0–14.0]/107 8.5 [6.0–13.0]/46 0.069 10.8 11.0 0.87
Non-respiratory SOFA 4.0 [4.0–5.0]/116 4.0 [4.0–4.0]/46 0.11 4.6 4.7 0.93
Vital Signs
Temperature, °C 36.9 [36.1–37.6]/141 36.8 [36.2–37.3]/54 0.79 36.9 36.8 0.82
Mean arterial pressure, mmHg 87.3 [79.7–95.0]/142 85.8 [78.0–92.0]/54 0.10 89.1 82.9 0.006
Heart rate, bpm 81.0 [73.0–91.0]/141 78.5 [66.0–88.0]/54 0.073 82.5 78.9 0.25
SpO2, % 90.0 [88.0–94.0]/141 90.0 [88.0–92.0]/54 0.57 90.4 90.4 0.99
Respiratory rate, bpm 25.0 [22.0–30.0]/136 23.0 [20.0–30.0]/54 0.081 25.7 25.5 0.87
Arterial blood gas
PaO2/FiO2 111.0 [83.0–144.0]/124 125.0 [99.0–187.0]/51 0.037 123.9 148.2 0.12
PaCO2, mmHg 33.1 [30.0–37.0]/129 34.7 [30.8–39.0]/51 0.23 34.7 34.0 0.54
Laboratory findings
Ferritin, ng/mL 1265 [755–1904]/87 934 [597–2092]/41 0.54 1640 1766 0.77
D-Dimer, ng/mL 925 [600.0–1800]/114 931 [549–1790]/48 0.77 1605 1608 0.99
CRP, mg/dL 16.82 [8.31–30.40]/131 21.51 [8.46–145.00]/53 0.20 56.39 57.7 0.93
Lymphocyte count, 10e3/μL 0.61 [0.40–0.90]/132 0.61 [0.40–0.89]/53 0.82 0.8 0.7 0.60
IL-6, pg/mL 135.0 [61.8–202.0]/17 93.0 [35.5–301.0]/11 0.20 186.6 134.4 0.47
LDH, U/L 396.0 [331.0–480.0]/125 380.0 [313.0–528.0]/51 0.27 417.3 434.3 0.61
Leukocytes, 103/μL 7.1 [5.0–11.2]/131 6.5 [4.4–9.0]/52 0.86 8.1 6.7 0.13
Procalcitonin, ng/mL 0.2 [0.1–0.6]/99 0.1 [0.1–0.3]/39 0.17 0.7 0.3 0.071
Platelets, 1000/mm3 232.0 [152.0–342.0]/133 233.0 [153.0–274.0]/53 0.12 261.9 221.3 0.043
Bilirrubin, mg/dL 0.6 [0.4–1.0]/124 0. 7 [0.5–0.9]/48 0.51 0.9 0.7 0.12
GPT, U/L 43.5 [23.0–78.0]/130 37.0 [25.5–71.0]/52 0.73 65.5 62.6 0.84
Creatinine, mg/dL 0.8 [0.6–1.1]/132 0.8 [0.7–1.0]/52 0.67 1.0 1.0 0.72
Urea, mg/dL 36.0 [27.2–53.0]/76 33.6 [21.0–49.0]/42 0.39 45.5 33.7 0.019
Troponin, ng/mL 14.0 [4.4–23.4]/69 8.0 [2.8–15.1]/33 0.061 17.3 13.2 0.46
NTproBNP, pg/mL 418.0 [125.5–1529.0]/16 225.5 [50.0–1263.0]/6 0.33 760.1 731.9 0.94
Hematocrit, % 38.0 [35.0–42.0]/126 40.7 [36.0–44.0]/50 0.041 38.7 39.4 0.63
Lactate, mmol/L 1.5 [1.0–2.1]/82 1.6 [1.3–2.00]/33 0.36 1.8 1.8 0.97
Values were obtained from each patient on day 1 of HFNT. Categorical variables are expressed as proportion, and continuous variables as median (IQR) for
original-eligible population and percentage and mean for weighted population
HFNO high-flow nasal oxygen therapy, COPD chronic obstructive pulmonary disease, SOFA Sequential Organ Failure Assessment, CRP C-reactive protein, IL
interleukin, LDH lactate dehydrogenase, GPT glutamate pyruvate transaminase
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This study has several strengths. First, to date, it is the
largest study including 199 patients from 36 intensive
care units. Second, this multicenter nationwide prospect-
ive daily data collection protocol provided a very detailed
description of the patient course during the study
period. Third, to the best of our knowledge, this is the
first study that prospectively explored the association be-
tween awake-PP and the risk for intubation in original
and adjusted COVID-19 samples with severe hypoxemic
ARF. However, we acknowledge some limitations. First,
we were unable to determine whether clinicians used
awake-PP as usual practice for COVID-19 patients or as
a rescue strategy. Second, as in our case report form,
prone was only considered when it was applied for > 16
h/day, we cannot extend our results to patients pronated
for shorter periods of time. Whether awake prone pos-
ition for less than 16 h/day could have reduced the risk
of intubation is not available from our data. The patients
in this group may have acted as an uncontrolled con-
founder minimizing the differences between groups.
Table 2 Clinical evolution (maximum or minimum values) of the original-eligible population and weighted population while treated
with HFNO
° Original sample Weighted sample








Non-respiratory SOFA 4.0 [4.00–5.00]/125 4.0 [4.00–5.00]/46 0.25 4.8 5.0 0.62
Vital signs
Temperature, °C 37.2 [36.50–38.00]/141 37.1 [36.60–37.80]/54 0.80 37.2 37.3 0.53
Mean arterial pressure, mmHg 77.0 [70.50–83.83]/140 76.2 [68.00–84.00]/54 0.59 77.8 73.4 0.053
Heart rate, bpm 85.0 [75.00–96.00]/141 85.0 [79.00–100.00]/54 0.62 87.2 91.4 0.26
SpO2, % 89.0 [86.00–92.00]/141 88.0 [84.00–90.00]/54 0.11 88.8 87.6 0.21
Respiratory rate minimum, bpm 21.0 [18.00–24.00]/141 19.0 [16.00–23.00]/54 0.004 20.8 19.7 0.23
Respiratory rate maximum, bpm 27.0 [24.00–32.00]/141 27.0 [23.00–30.00]/54 0.49 27.7 27.1 0.64
Arterial blood gas
PaO2/FiO2 92.5 [77.00–125.50]/128 103.0 [80.00–125.00]/53 0.45 109.7 113.8 0.67
PaCO2, mmHg 39.9 [35.50–48.00]/131 41.2 [36.20–46.00]/53 0.56 44.8 42.4 0.29
Laboratory findings
Ferritin, ng/mL 1279.0 [694.00–2151.00]/107 1499.0 [809.00–2425.00]/45 0.45 1817.2 1955.0 0.75
D-Dimer, ng/mL 1681.0 [820.00–4200.00]/122 1590.0 [1030.00–3200.00]/50 0.98 2799.7 2624.9 0.76
CRP, mg/dL 21.3 [9.32–33.19]/132 22.7 [8.66–146.14]/53 0.23 62.4 62.6 0.98
Lymphocytes, μL 0.47 [0.30–0.74]/135 0.44 [0.30–0.60]/53 0.31 0.56 0.42 0.021
IL-6, pg/mL 177.0 [42.70–415.90]/17 87.5 [24.00–301.00]/14 0.34 832.7 221.6 0.33
LDH, U/L 429.0 [345.00–561.00]/125 449.0 [352.00–602.00]/51 0.51 451.2 490.3 0.29
Leukocytes, 103/μL 8.3 [5.80–12.00]/122 7.7 [5.21–12.33]/51 0.75 9.7 9.0 0.60
Procalcitonin, ng/mL 0.22 [0.11–0.57]/114 0.20 [0.09–0.34]/45 0.57 1.24 0.34 0.10
Platelets, 1000/mm3 319.0 [212.50–410.50]/136 303.0 [244.00–358.00]/53 0.64 330.6 329.7 0.97
Bilirrubin, mg/dL 0.80 [0.50–1.10]/130 0.84 [0.60–1.18]/50 0.33 1.23 0.90 0.052
ALT, U/L 66.0 [30.00–104.00]/135 52.0 [32.00–116.00]/53 0.82 85.2 105.6 0.35
Creatinin, mg/dL 0.90 [0.70–1.18]/136 0.86 [0.75–1.02]/52 0.45 1.10 1.09 0.96
Urea, mg/dL 42.0 [30.00–64.00]/91 39.5 [26.00–61.00]/50 0.44 52.0 42.7 0.12
Troponin, ng/mL 11.8 [4.30–25.00]/89 9.6 [4.60–27.52]/39 0.69 18.8 9.3 0.27
NTproBNP, pg/mL 335.5 [125.50–938.80]/20 303.1 [91.00–1019.00]/14 0.75 727.9 660.9 0.82
Hematocrit, % 38.00 [34.70–42.00]/111 39.20 [36.00–42.50]/45 0.97 38.2 39.4 0.35
Lactate, mmol/L 1.5 [1.16–2.10]/77 1.5 [1.20–2.10]/31 0.60 1.85 1.88 0.91
Maximum or minimum values during the period of HFNO. Categorical variables are expressed as proportion, and continuous variables as median (IQR) for original-
eligible population and percentage and mean for weighted population
HFNO high-flow nasal oxygen therapy, SpO2 peripheral oxyhemoglobin saturation, SOFA Sequential Organ Failure Assessment, RCP C-reactive protein, IL
interleukin, LDH lactate dehydrogenase, GPT glutamate pyruvate transaminase
Ferrando et al. Critical Care          (2020) 24:597 Page 7 of 11
This should be further investigated in a randomized con-
trolled trial. Third, intubation criteria were not uni-
formly defined and protocolized, which may limit the
generalizability of our results. Fourth, although we con-
trolled for variables describing patient’s severity, we ac-
knowledge that despite our efforts to control for this
possible source of bias, there is a risk of residual con-
founding or unrecognized biases. Fifth, due to the nature
of the database, the sample size was not calculated and
therefore the number of patients included in this ana-
lysis could be less than necessary to have adequate
power for the primary endpoint. However, an ongoing
RCT (NCT04347941) includes a total of 200 patients,
which is very similar to our 199 patients, to demonstrate
the effects of awake prone position on intubation in
COVID-19 patients with ARF. Finally, due to the prag-
matic nature of our data collection, variables such as
SpO2, PaO2/FiO2, RR, or ROX index were not collected
before and after awake-PP sessions. Therefore, individual
responses could not be determined, limiting the possibil-
ity of analyzing the effects of prone on intubation in
Table 3 Associations between HFNO plus awake prone
positioning and the endpoint of intubation and 28-day
mortality in the original population and weighted population
Analysis Hazard ratio (95% CI);
p value
Intubation
Crude analysis 0.879 (0.538, 1.435); p = 0.60
Inverse probability weighting analysis 1.002 (0.531, 1.890); p = 0.99
28-day mortality
Crude analysis 1.046 (0.402, 2.722); p = 0.92
Inverse probability weighting analysis 2.411 (0.556, 10.442); p = 0.23
Logistic models were fitted to predict treatment at baseline using the
following variables as predictors of treatment: age, sex, obesity, non-
respiratory sequential organ failure assessment severity score, APACHE II, C-
reactive protein, days from symptoms onset to high-flow nasal therapy start,
respiratory rate, and peripheral oxyhemoglobin saturation
CI confidence interval
Fig. 2 Time to event curves using Kaplan-Meier with multivariate Cox regression. The probability of been intubated in the original (top-left) and
weighted (top-right) samples and the probability of 28-day mortality in the original (bottom-left) and weighted (bottom-right) samples were not
affected by the use of awake prone positioning. HFNO, high-flow nasal oxygen therapy; HFNO + awake-PP, high-flow nasal oxygen therapy plus
awake prone positioning
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specific subpopulations of patients. Nevertheless, current
data showed that responders, defined as those patients
that improved oxygenation when managed with HFNO
and awake-PP, did not decrease their risk for intubation.
Conclusions
To the best of our knowledge, this is the first multicen-
ter study that prospectively evaluated the benefits and
the role of HFNO combined with awake prone position-
ing in the prevention of intubation in an adjusted large
cohort of COVID-19 patients. We found that this com-
bined approach did not reduce the risk of intubation,
but could increase the risk of delaying intubation. In the
current study, awake-PP did not affect 28-day mortality.
The interpretation of these results may be limited by the
observational design, and therefore future studies are
needed to identify potential subpopulations that may
benefit from awake prone positioning in COVID-19 pa-
tients with acute hypoxemic respiratory failure.
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